The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Open accessAbstract
Objective.: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA). Methods.: Data were pooled from 2 open-label studies (NCT00413699,NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib. Safety data included over 60 months of observation; efficacy data are reported up to Month 48. Treatment was initiated with tofacitinib 5 or 10 mg twice daily. Primary endpoints were adverse events (AE) and laboratory safety data. Secondary endpoints included American College of Rheumatology (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments. Results.: Overall, 4102 patients were treated for 5963 patient-years; mean (maximum) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 months. The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%). Serious AE were reported in 15.4% of patients with an exposure-estimated incidence rate of 11.1 events/100 patient-years. Serious infections were reported in 4.5% of patients with an exposure-estimated incidence rate of 3.1 events/100 patient-years (95% CI: 2.66–3.55). Mean values for laboratory variables were stable over time and consistent with phase II and III studies. Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI. Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiologic disease-modifying antirheumatic drugs. Conclusion.: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 months in patients with RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Self-citationTofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Self-citationDixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Burmester, G. R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61424-x · Cited by 714
Self-citationGalloway, J. B., Hyrich, K. L., Mercer, L. K., Dixon, W. G., Fu, B., Ustianowski, A. P., Watson, K. D., Lunt, M., BSRBR Control Centre Consortium, Symmons, D. P. M., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/keq242 · Cited by 676
Carmona, L., Gómez‐Reino, J. J., Rodríguez‐Valverde, V., Montero, D., Pascual‐Gómez, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21043 · Cited by 656
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Self-citationKremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Self-citationRisk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Wolfe, F., Michaud, K., Anderson, J., & Urbansky, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20009 · Cited by 431
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33383 · Cited by 376
Self-citationThe widening mortality gap between rheumatoid arthritis patients and the general population
Gonzalez, A., Maradit Kremers, H., Crowson, C. S., Nicola, P. J., Davis, J. M., Therneau, T. M., Roger, V. L., & Gabriel, S. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22979 · Cited by 357
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Winthrop, K. L., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., Kawabata, T., & Riese, R. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38745 · Cited by 353
Self-citationKremer, J. M., Cohen, S., Wilkinson, B. E., Connell, C. A., French, J. L., Gomez‐Reino, J., Gruben, D., Kanik, K. S., Krishnaswami, S., Pascual‐Ramos, V., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33419 · Cited by 344
Self-citationTanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S. H., & Tofacitinib Study Investigators (2011) · Arthritis Care & Research · doi:10.1002/acr.20494 · Cited by 297
Self-citationSmitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23112 · Cited by 281
Antirheumatic Drugs and the Risk of Tuberculosis
Brassard, P., Kezouh, A., & Suissa, S. (2006) · Clinical Infectious Diseases · doi:10.1086/506935 · Cited by 266
Increased risk of tuberculosis in patients with rheumatoid arthritis.
Carmona, L., Hernández‐García, C., Vadillo, C., Pato, E., Balsa, A., González‐Álvaro, I., Belmonte, M. Á., Tena, X., & Sanmartí, R. (2003) · PubMed · Cited by 233
Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis
McDonald, J. R., Zeringue, A. L., Caplan, L., Ranganathan, P., Xian, H., Burroughs, T. E., Fraser, V. J., Cunningham, F., & Eisen, S. A. (2009) · Clinical Infectious Diseases · doi:10.1086/598331 · Cited by 218
Burmester, G. R., Xavier Mariette, A., Montecucco, C., Sáez, I. M., Malaise, M., Tzioufas, A. G., Bijlsma, J. W. J., Unnebrink, K., Kary, S., & Küpper, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066761 · Cited by 202
Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
Sichletidis, L. T., Settas, L., Spyratos, D. G., Chloros, D., & Patakas, D. (2006) · PubMed · Cited by 198
Galloway, J. B., Mercer, L. K., Moseley, A., Dixon, W. G., Ustianowski, A. P., Helbert, M., Watson, K. D., Lunt, M., Hyrich, K. L., & Symmons, D. P. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201108 · Cited by 174
Serious infections during anti-TNFα treatment in rheumatoid arthritis patients
Favalli, E. G., Desiati, F., Atzeni, F., Sarzi‐Puttini, P., Caporali, R. F., Bobbio‐Pallavicini, F., Gorla, R., Filippini, M., & Marchesoni, A. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.11.002 · Cited by 164
Wolfe, F., Michaud, K. D., & Chakravarty, E. F. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel328 · Cited by 153
Björnådal, L., Baecklund, E., Yin, L., Granath, F., Klareskog, L., & Ekbom, A. (2002) · PubMed · Cited by 130
McInnes, I. B., Kim, H., Lee, S., Mandel, D. R., Song, Y.-W., Connell, C. A., Luo, Z., Brosnan, M. J., Zuckerman, A. L., Zwillich, S. H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202442 · Cited by 127
Self-citationGarcía-Doval, I., Pérez-Zafrilla, B., Descalzo, M. Á., Roselló, R., Hernández, M. V., Gómez-Reino, J. J., & Carmona, L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.125658 · Cited by 108
Kievit, W., Fransen, J., Adang, E., den Broeder, A. A., Moens, H. J. B., VISSER, H. K. A., van de Laar, M. A. F., & van Riel, P. L. C. M. (2010) · Rheumatology · doi:10.1093/rheumatology/keq325 · Cited by 108
Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate
Antonelli, M. A. S., Moreland, L. W., & Brick, J. E. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80008-a · Cited by 99
Sakellariou, G., Scirè, C. A., Verstappen, S. M. M., Montecucco, C., & Caporali, R. F. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201817 · Cited by 98
The incidence of gastrointestinal perforations among rheumatoid arthritis patients
Curtis, J. R., Xie, F., Chen, L., Spettell, C. M., Mcmahan, R. M., Fernandes, J. F., & Delzell, E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30107 · Cited by 92
Self-citationCurtis, J. R., Lanas, Á., John, A. K., Johnson, D. A., & Schulman, K. L. (2012) · Arthritis Care & Research · doi:10.1002/acr.21764 · Cited by 71
Self-citationWinthrop, K. L., Neal, J., Hrycaj, P., Soma, K., Wilkinson, B. E., Hodge, J., Zwillich, S. H., Wang, T., Rottinghaus, S. T., Kawabata, T. T., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-eular.368 · Cited by 4
Self-citationIsaacs, J. D., Nduaka, C. I., Zuckerman, A., Krishnaswami, S., Riese, R. J., Lan, S.-P., Hutmacher, M. M., Boy, M. G., & Bradley, J. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-eular.595 · Cited by 2
Self-citation
Cited by
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
“Clinically significant hepatic and renal compromise have not been reported; however, [92] a phase I randomized controlled trial assessed changes in serum creatinine and glomerular filtration rate in RA patients treated with tofacitinib and compared them with patients who received placebo.”
BackgroundResultInfluentialKinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Metadata
- Authors
- Wollenhaupt, J., Silverfield, J., Lee, E. B., Curtis, J. R., Wood, S. P., Soma, K., Nduaka, C. I., Benda, B., Gruben, D., Nakamura, H., Komuro, Y., Zwillich, S. H., Wang, L., & Riese, R. J.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2014-04-01
- Volume
- 41
- Issue
- 5
- Pages
- 837-852
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2046744512
- Cited by
- 301
- References
- 37
- FWCI
- 23.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.